Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ondine Biomedical's enterprise value is €77.10 Mil.
Ondine Biomedical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-18.08 Mil. Therefore, Ondine Biomedical's EV-to-EBITDA for today is -4.26.
The historical rank and industry rank for Ondine Biomedical's EV-to-EBITDA or its related term are showing as below:
FRA:VF5'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.58 Med: -1.92 Max: 0.04
Current: -4.22
During the past 13 years, the highest EV-to-EBITDA of Ondine Biomedical was 0.04. The lowest was -15.58. And the median was -1.92.
FRA:VF5's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.3
vs FRA:VF5: -4.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ondine Biomedical's PE Ratio (TTM) for today is calculated as:
Ondine Biomedical's share price for today is €0.133.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ondine Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.038.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ondine Biomedical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VF5 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Ondine Biomedical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's EV-to-EBITDA falls into.
Ondine Biomedical's current Enterprise Value is €77.10 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ondine Biomedical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-18.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ondine Biomedical (FRA:VF5) has a EV-to-EBITDA of -4.26 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ondine Biomedical. According to the industry distribution chart, Ondine Biomedical ranks #999999 out of 402 companies in the Biotechnology industry.
Is Ondine Biomedical's EV-to-EBITDA too high?
Ondine Biomedical's current EV-to-EBITDA is -4.26. Based on the distribution chart, Ondine Biomedical ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ondine Biomedical has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #999999 out of 402 companies for EV-to-EBITDA. This places Ondine Biomedical in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.30, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ondine Biomedical. For the Biotechnology industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ondine Biomedical's current EV-to-EBITDA is -4.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.13 — trading 47.8% above its estimated fair value. The current EV-to-EBITDA is -4.26. Ondine Biomedical's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current EV-to-EBITDA is -4.26 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of €0.13 is trading 47.8% above its estimated GF Value™ of €0.09.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for FRA:VF5:
EV-to-EBITDA: -4.26
GF Value™: €0.09 vs. price of €0.13 (47.8% above fair value)
No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
41GF Score
Get the complete analysis for FRA:VF5
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
